Lipophilic statin use and risk of breast cancer subtypes.
Summary of "Lipophilic statin use and risk of breast cancer subtypes."
Background/Aims: Statins are widely used and of high interest as potential chemopreventive agents for cancer. Preclinical studies suggest that lipophilic statins have anti-cancer properties targeting hormone receptor (HR)-negative breast cancer. Few epidemiologic studies have investigated the relationship between lipophilic statin use and risk of breast cancer, stratified by HR status. We conducted a large case-control study within the Kaiser Permanente of Northern California (KPNC) to determine whether chronic use of lipophilic statins is associated with decreased risk of HR-negative breast cancer, or other breast cancer subtypes.
We identified 22,488 breast cancer cases diagnosed during 1997-2007, and 224,860 controls matched to cases based upon birth year and duration of KPNC pharmacy coverage. Use of lipophilic statins was ascertained using KPNC's comprehensive electronic pharmacy records.
We found no association between lipophilic statin use (>/=2 years vs. never) and overall breast cancer risk (OR(adj)=1.02; 95%CI=0.97-1.08) in conditional logistic regression models adjusted for oral contraceptive and hormone therapy use. Women who used lipophilic statins did not have a decreased risk of HR-negative breast cancer (OR(adj)=0.98; 95%CI=0.84-1.14), nor altered risk of HR-positive disease (OR(adj)=1.03; 95%CI=0.97-1.10). Furthermore, lipophilic statin use was not associated with risk of any of the intrinsic subtypes, luminal A, luminal B, HER2+/ER- or triple negative.
Our results do not support an association of lipophilic statin use with the risk of breast cancer in general or with risks of HR-negative or other breast cancer subtypes specifically. Impact: These findings do not confirm previous reports of a possible preventive association.
1Laboratory of Molecular Pharmacology, National Cancer Institute.
This article was published in the following journal.
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20729289
- DOI: http://dx.doi.org/10.1158/1055-9965.EPI-10-0524
Background:Limited data suggest that statin use reduces the risk for ovarian cancer.Methods:Using Danish nationwide registries, we identified 4103 cases of epithelial ovarian cancer during 2000-2011 a...
Breast cancer is a heterogeneous disease with intrinsic molecular subtypes. The different biology and histology of breast cancer exhibit different tumor morphology at breast magnetic resonance imaging...
Several advancements over the last decade have triggered the developments in the field of breast cancer risk research. One of them is the availability of the human genome sequence along with cheap gen...
Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with inc...
Breast cancer is one of the most common cancers and the first-leading cause of cancer deaths among women in the world. Indeed, breast cancer is ranked as the first malignancy among Iranian women. Brea...
The purpose of this study is to monitor: - Tumor biological alterations following two weeks of neo-adjuvant statin therapy. - Effects of statins on tumor proliferation. - ...
RATIONALE: Studying mammograms for breast density changes over time may help doctors predict breast cancer risk. PURPOSE: This natural history study is looking at changes in breast densit...
The purpose of this study is to evaluate the effectiveness and safety of Trabectedin in three subpopulations of breast cancer patients.
Magnetic Resonance Imaging (MRI) is a well known imaging tool for the investigation and diagnosis of breast cancer, used in addition to breast mammograms and ultrasound. Recent publication...
Objectives: - To screen population with high risk for breast cancer - To promote the concept and importance of surveillance mammography - To find out the incidence of bre...
Medical and Biotech [MESH] Definitions
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.